Please login to the form below

Not currently logged in
Email:
Password:

Crohn's Disease

This page shows the latest Crohn's Disease news and features for those working in and with pharma, biotech and healthcare.

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020

The five are all “potential blockbusters”, according to Celgene’s chief executive Mark Alles on the company’s third-quarter results call. ... registration trial in this indication – TRUE NORTH – as well as studies in Crohn’s disease.

Latest news

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS also highlighted new data with BMS’ selective TYK2 inhibitor for moderate to severe plaque psoriasis, which has moved into phase 3 and is also in mid-stage testing for ... s disease, ulcerative colitis and lupus.

  • First Humira biosimilars reach EU market First Humira biosimilars reach EU market

    AbbVie’s patent protection for Humira (adalimumab) has come to an end in Europe. ... diseases including rheumatoid arthritis, psoriasis and Crohn's disease.

  • BMS psoriasis drug hits the mark in phase II BMS psoriasis drug hits the mark in phase II

    presence than BMS in the inflammatory disease market. ... BMS also has phase II studies of the drug ongoing in other indications including systemic lupus erythematosus and Crohn's disease.

  • Gilead and Galapagos JAK contender scores in RA trial Gilead and Galapagos JAK contender scores in RA trial

    The results are further good news for the partners and their inflammatory conditions contender, which is also being studied in ulcerative colitis, Crohn’s disease and ankylosing spondylitis. ... John McHutchinson. John McHutchison, MD, chief scientific

  • Gilead, Galapagos JAK inhibitor clears phase II test Gilead, Galapagos JAK inhibitor clears phase II test

    The drug is also in development for rheumatoid arthritis (RA), ulcerative colitis and Crohn’s disease with phase III trials already underway in those indications and results due in the coming ... Like filgotinib, upadacitinib is also being tested in a

More from news
Approximately 18 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease.  The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to ... However, there is a movement towards greater research in this

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... These will be used to aid in decision-making and help

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics